Trugilho Monique R O, Azevedo-Quintanilha Isaclaudia G, Gesto João S M, Moraes Emilly Caroline S, Mandacaru Samuel C, Campos Mariana M, Oliveira Douglas M, Dias Suelen S G, Bastos Viviane A, Santos Marlon D M, Carvalho Paulo C, Valente Richard H, Hottz Eugenio D, Bozza Fernando A, Souza Thiago Moreno L, Perales Jonas, Bozza Patrícia T
Center for Technological Development in Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Laboratory of Toxinology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Cell Death Discov. 2022 Jul 16;8(1):324. doi: 10.1038/s41420-022-01122-1.
Coronavirus disease 2019 (COVID-19) has affected over 400 million people worldwide, leading to 6 million deaths. Among the complex symptomatology of COVID-19, hypercoagulation and thrombosis have been described to directly contribute to lethality, pointing out platelets as an important SARS-CoV-2 target. In this work, we explored the platelet proteome of COVID-19 patients through a label-free shotgun proteomics approach to identify platelet responses to infection, as well as validation experiments in a larger patient cohort. Exclusively detected proteins (EPs) and differentially expressed proteins (DEPs) were identified in the proteomic dataset and thus classified into biological processes to map pathways correlated with pathogenesis. Significant changes in the expression of proteins related to platelet activation, cell death, and antiviral response through interferon type-I were found in all patients. Since the outcome of COVID-19 varies highly among individuals, we also performed a cross-comparison of proteins found in survivors and nonsurvivors. Proteins belonging to the translation pathway were strongly highlighted in the nonsurvivor group. Moreover, the SARS-CoV-2 genome was fully sequenced in platelets from five patients, indicating viral internalization and preprocessing, with CD147 as a potential entry route. In summary, platelets play a significant role in COVID-19 pathogenesis via platelet activation, antiviral response, and disease severity.
2019冠状病毒病(COVID-19)已影响全球超过4亿人,导致600万人死亡。在COVID-19复杂的症状中,高凝和血栓形成被认为直接导致了致死率,血小板被指出是严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的一个重要靶点。在这项研究中,我们通过无标记鸟枪法蛋白质组学方法探索了COVID-19患者的血小板蛋白质组,以确定血小板对感染的反应,以及在更大的患者队列中进行验证实验。在蛋白质组数据集中鉴定出独家检测蛋白(EPs)和差异表达蛋白(DEPs),并将其分类到生物学过程中,以绘制与发病机制相关的通路。在所有患者中均发现与血小板活化、细胞死亡及通过I型干扰素的抗病毒反应相关的蛋白质表达有显著变化。由于COVID-19的预后在个体间差异很大,我们还对幸存者和非幸存者体内发现的蛋白质进行了交叉比较。在非幸存者组中,属于翻译途径的蛋白质被强烈凸显。此外,对5例患者的血小板中的SARS-CoV-2基因组进行了全测序,表明病毒发生内化和预处理,CD147可能是病毒的进入途径。总之,血小板通过血小板活化、抗病毒反应及疾病严重程度在COVID-19发病机制中发挥重要作用。